Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Carillon Eagle Small Cap Growth Fund Eric Mintz, Christopher Sassouni, David Cavanaugh | “iRhythm Technologies is a digital healthcare company that develops wearable, AI-driven cardiac monitoring devices. The stock struggled despite delivering beat-and-raise results. Broader weakness in the healthcare equipment and supplies industry, as investors rotated into cyclical and technology stocks, weighed on performance. Additional pressure came from a US Department of Justice Civil Investigative Demand (DOJ CID) received in December related to mobile cardiac telemetry services rendered in 2023 via iRhythm's Zio AT recording device. This inquiry is limited in scope as it only accounts for a small portion of total sales and the risk has already been priced in. We don't read too much into the company's recent change of auditors.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Carillon Eagle Growth & Income Fund Brad Erwin, Jeffrey D. Bilsky, Michael Rich | “iRhythm Technologies is a digital healthcare company that develops wearable, AI-driven cardiac monitoring devices. The stock struggled despite delivering beat-and-raise results. Broader weakness in th” | BULL | Q1 2026 Apr 18, 2026 | View Pitch |
Artisan Global Discovery Jason White | “In addition to Coherent, notable trims in the quarter included iRhythm. iRhythm develops the Zio wearable patch for cardiac monitoring. The company delivered a strong quarter with solid growth in its core services, improving cash flow trends and raised full-year guidance, while its mobile cardiac telemetry (MCT) device remains under FDA review. We trimmed the position to take profits after a strong year, as growth may moderate in 2026 with fewer near-term catalysts despite an attractive long-term outlook. BSD Analysis: iRhythm is a transformative digital healthcare leader, specializing in AI-driven continuous cardiac monitoring through its Zio platform. For 2026, the company is entering a high-growth phase with projected revenue growth of 17% to 18% as it deepens its penetration in primary care and population health. A major catalyst for the year is the achievement of sustained free cash flow positivity, a milestone that significantly de-risks the investment narrative. The company's extensive clinical evidence program continues to prove Zio's superiority over traditional short-term monitors, supporting its expansion into international markets and adjacent care settings. While valuation remains a consideration, the massive addressable market for ambulatory cardiac monitoring provides a long runway for revenue scaling. As payer support for digital health solutions increases, iRhythm's integrated data-and-device model is well-positioned to become the standard of care.” | BULL | Q4 2025 Jan 27, 2026 | View Pitch |
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Along with Coherent, other notable trims during the quarter were iRhythm and MACOM. iRhythm provides the Zio wearable cardiac monitoring devices to assist physicians in diagnosing cases of cardiac arrhythmias that signal elevated stroke risks. The company delivered a strong quarter that included solid growth in its core services and improving cash flow trends. After a strong 2025 driven by company-specific profit cycle tailwinds and market share gains, we trimmed the position to take profits and right-size the investment. Growth may moderate in 2026 ahead of what we expect to be another compelling product cycle beginning in 2027. BSD Analysis: iRhythm sits at the intersection of cardiac diagnostics, data, and workflow integration, where outcomes matter more than cost. Its continuous monitoring platform is embedded into physician decision-making, creating stickier adoption than one-off devices. Reimbursement clarity has improved, removing a major overhang. Growth remains strong as arrhythmia detection moves earlier in care pathways. Investors worry about losses and scaling costs. But operating leverage emerges quickly once utilization rises. Clinical data remains the core moat. This is diagnostics adoption, not gadget churn. Execution now matters more than awareness.” | BULL | Q4 2025 Jan 15, 2026 | View Pitch |
Artisan Partners Small Cap Fund Jay Warner | “iRhythm develops and markets the Zio, a wearable patch that monitors irregular heartbeats. Its advanced technology is well positioned for broad adoption as doctors and insurers push for earlier detection of atrial fibrillation to prevent strokes. Shares climbed after strong earnings, with 20% revenue growth and gross margins rising to 69% thanks to scaling and efficiency gains. Management also raised its forward guidance. BSD Analysis: iRhythm's strong top-line acceleration and improving margins reflect growing adoption of Zio and scaling benefits in diagnostics. With reimbursement visibility improving and digital cardiology gaining traction, iRhythm supports a premium valuation. The company's recurring-revenue model and clinical differentiation provide durable competitive advantages. Key risks include regulatory scrutiny and competition in cardiac monitoring.” | BULL | Q2 2025 Jul 22, 2025 | View Pitch |
Artisan Global Discovery Jason White | “iRhythm develops and markets the Zio, a wearable patch that monitors irregular heartbeats. Its advanced technology is well positioned for broad adoption as doctors and insurers push for earlier detection of atrial fibrillation to prevent strokes. Shares climbed after strong earnings, with 20% revenue growth and gross margins rising to 69% thanks to scaling and efficiency gains. Management also raised its forward guidance. BSD Analysis: iRhythm is the category killer in ambulatory cardiac monitoring — a medtech disruptor replacing bulky Holter monitors with Zio patches that cardiologists and patients actually prefer. Reimbursement noise hurt sentiment, but adoption keeps climbing because Zio produces better data, faster diagnoses, and happier doctors. Margins are recovering as scale increases, and iRhythm still has a long runway as arrhythmia prevalence rises with aging demographics. Once pricing stabilizes, this business snaps back hard. It's a premium clinical-data platform masquerading as a device company.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
